Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Opella Healthcare Group SAS has 3 pending office actions in Biotechnology & Pharmaceuticals. Each action is assigned to a separate examiner and art unit, producing a fully distributed docket at this scale.
GOTFREDSON, GAREN is the busiest examiner, with 1 pending action. No examiner has multiple pending matters in the supplied data, so prosecution planning should focus on matter-specific preparation rather than examiner-wide coordination. The separate art-unit assignments also call for individualized technical and procedural review.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GOTFREDSON, GAREN | 1 | 39.9% | +28.1% |
| BAUER, NICOLA MARIA | 1 | 58.7% | +52.1% |
| PHAN, DOAN THI-THUC | 1 | 42.8% | +47.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18265107 | COMPOSITION CONTAINING RANITIDINE HAVING A LOW IRON CONTENT | PHAN, DOAN THI-THUC | 55d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19355572 | PARABEN-FREE FEXOFENADINE FORMULATIONS | GOTFREDSON, GAREN | 55d |
| 18265107 | COMPOSITION CONTAINING RANITIDINE HAVING A LOW IRON CONTENT | PHAN, DOAN THI-THUC | 55d |
| 18725446 | COMPOSITIONS CONTAINING FEXOFENADINE | BAUER, NICOLA MARIA | — |
| Art Unit | Apps |
|---|---|
| 1619 | 1 |
| 1621 | 1 |
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19355572 | PARABEN-FREE FEXOFENADINE FORMULATIONS | GOTFREDSON, GAREN | 1619 | §103 | Non-Final OA | 55d | Pending | Oct 10, 2025 |
| 18725446 | COMPOSITIONS CONTAINING FEXOFENADINE | BAUER, NICOLA MARIA | 1621 | §103 | Non-Final OA | — | Pending | Jun 28, 2024 |
| 18265107 | COMPOSITION CONTAINING RANITIDINE HAVING A LOW IRON CONTENT | PHAN, DOAN THI-THUC | 1613 | §103§112 | Final Rejection | 55d | Pending | Jun 02, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOpella Healthcare Group SAS has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Garen Gotfredson has the most, with 1 of Opella Healthcare Group SAS's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
